The M&A Advisor has awarded Troutman Pepper Three Turnaround Awards – Financial Deal of the Year, SEC.363 Sale of the Year (over $250MM), and Restructuring of the Year ($10MM to $50MM). The awards are part of The M&A Advisor’s 18thAnnual Turnaround Awards program, which recognizes the leading distressed transactions, restructuring, refinancing, products and services, firms, and professionals in the United States and international markets. The nominations, representing over 250 participating companies, were judged by an independent panel of industry experts.
Financials Deal of the Year
The Financials Deal of the Year award recognized the Section 363 acquisition of Plastiq, Inc. by Priority Technology Holdings, Inc. Troutman Pepper’s Matthew Brooks, James Stevens, Brenna Sheffield, Sarah Hanna, David Fournier and Tori Lynn Remington advised Priority Technology Holdings, Inc. in the acquisition.
SEC.363 Sale of the Year (Over $250MM)
Troutman Pepper received the SEC.363 Sale of the Year (Over $250MM) for its representation of Hikma Pharmaceuticals USA as the successful bidder for the assets of Akorn, a generics manufacturer. Troutman Pepper’s Deborah Kovsky-Apap, Chris Miller, Judith O’Grady, Erin Whaley, Matthew Swett, Samantha Peruto, and Emma Trivax advised Hikma in the transaction.
Restructuring of the Year ($10MM to $50MM)
Troutman Pepper represented the QHC Facilities, LLC Committee of Unsecured Creditors and now the liquidating trust in connection with a Chapter 11 pending in Iowa involving ten assisted living and nursing home facilities that service more than 300 residents. Troutman Pepper’s Francis Lawall and Deborah Kovsky-Apap advised QHC in the restructuring.
The firm is a market leader in both the financial services and health sciences industries which these deals span.
Troutman Pepper’s Financial Services Group provides comprehensive support to all types of financial services businesses in today’s challenging and ever-changing environment. The team includes more than 200 attorneys who regularly advise national, regional, and community banks, financial technology companies, payments companies, consumer and commercial lenders, and a wide variety of other financial services businesses on the most crucial aspects of their business, from structuring major transactions to dealing with regulatory scrutiny and litigation.
The firm is also a go-to firm for life sciences transactions with a large, multidisciplinary team with a deep understanding of the space. The firm regularly advises pharmaceutical, biotech, medical device, diagnostics, and other life sciences clients on all types of corporate matters — governance and general corporate advice; M&A transactions; licensing transactions and other complex collaborations; IPOs, follow-on public offerings, PIPE transactions, and other capital markets transactions; seed and later-stage venture capital financings; and much more.
Winners of the 18thAnnual Turnaround Awards will be recognized at the 2024 Distressed Investing Summit on March 19.
Original source can be found here.